Mymetics Corporation (OTCQB: MYMX). We develop next-generation of prophylactic vaccines for infectious and life disabling diseases based on virosomes, lipid-based carriers containing functional fusion viral proteins and natural membrane proteins and specifically designed antigens.

Cooperation possibilities

Collaboration on specific vaccine candidate for enveloped viruses to create virosome based vaccine that need the fusion capability maintained and antigens that need safe and effective carrier (virosome). Out licensing possibility for our intra-nasal influenza vaccine that has successfully finished Phase I.

Location
Facts & figures
  • Type of organization
    Public company
  • Year of foundation
    2000
  • Number of employees in Switzerland
    1-9